MiNK Therapeutics annual stock-based compensation
2020
2021
2022
2023
2024
2025
MiNK Therapeutics Stock-Based Compensation Growth & History (INKT)
MiNK Therapeutics's stock-based compensation was $2.7M for fiscal 2025.
View full MiNK Therapeutics company overviewMiNK Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $2.7M | $863,771 | +47.72% |
| 2024 | 2024-12-31 | $1.8M | −$2.1M | −53.11% |
| 2023 | 2023-12-31 | $3.9M | $833,520 | +27.54% |
| 2022 | 2022-12-31 | $3.0M | $1.3M | +73.49% |
| 2021 | 2021-12-31 | $1.7M | $1.7M | +1886.50% |
| 2020 | 2020-12-31 | $87,829 | — | — |
MiNK Therapeutics quarterly stock-based compensation
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $422,202 | −$474,350 | −52.91% |
| Q1 2026 | 2026-03-31 | $630,386 | $39,297 | +6.65% |
| Q4 2025 | 2025-12-31 | $565,771 | $175,723 | +45.05% |
| Q3 2025 | 2025-09-30 | $620,585 | $229,287 | +58.60% |
| Q2 2025 | 2025-06-30 | $896,552 | $459,678 | +105.22% |
| Q1 2025 | 2025-03-31 | $591,089 | −$917 | −0.15% |
| Q4 2024 | 2024-12-31 | $390,048 | −$711,650 | −64.60% |
| Q3 2024 | 2024-09-30 | $391,298 | −$547,966 | −58.34% |
| Q2 2024 | 2024-06-30 | $436,874 | −$461,391 | −51.36% |
| Q1 2024 | 2024-03-31 | $592,006 | −$329,133 | −35.73% |
| Q4 2023 | 2023-12-31 | $1.1M | $434,067 | +65.02% |
| Q3 2023 | 2023-09-30 | $939,264 | $166,365 | +21.52% |
| Q2 2023 | 2023-06-30 | $898,265 | $97,455 | +12.17% |
| Q1 2023 | 2023-03-31 | $921,139 | $135,633 | +17.27% |
| Q4 2022 | 2022-12-31 | $667,631 | $602 | +0.09% |
| Q3 2022 | 2022-09-30 | $772,899 | $385,537 | +99.53% |
| Q2 2022 | 2022-06-30 | $800,810 | $393,507 | +96.61% |
| Q1 2022 | 2022-03-31 | $785,506 | $502,476 | +177.53% |
| Q4 2021 | 2021-12-31 | $667,029 | — | — |
| Q3 2021 | 2021-09-30 | $387,362 | $376,608 | +3502.03% |
| Q2 2021 | 2021-06-30 | $407,303 | — | — |
| Q1 2021 | 2021-03-31 | $283,030 | — | — |
| Q3 2020 | 2020-09-30 | $10,754 | — | — |
MiNK Therapeutics stock-based compensation trends
Over the last five fiscal years, MiNK Therapeutics's stock-based compensation increased from $87,829 to $2.7M, a change of $2.6M. The latest reported quarter, Q2 2026, shows $422,202.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review MiNK Therapeutics source filings ↗